Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. (Q51379841)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2012

Language	Label	Description	Also known as
English	Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.	scientific article published in March 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

anti-retroviral agent

0 references

14

object named as

R S Hogg

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

author name string

J Raboud

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

A Anema

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

D Su

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

M B Klein

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

A Zakaryan

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

T Swan

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

A Palmer

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

S Hosein

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

M R Loutfy

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

N Machouf

10

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

J S G Montaner

11

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

S B Rourke

12

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

C Tsoukas

13

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

C Cooper

15

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Canadian Observational Cohort (CANOC) Collaboration

16

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

publication date

1 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

13

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

90-102

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The prognostic value of a single hepatitis C virus RNA load measurement taken early after human immunodeficiency virus seroconversion

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

HIV and hepatitis C coinfection within the CAESAR study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Hepatitis C and Innate Immunity: Recent Advances

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Lower CD4+ T-cell number expressing CD7+ characterizes HIV/hepatitis C virus coinfection compared with HIV and hepatitis C virus monoinfection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Cognitive dysfunction in chronic hepatitis C: a review

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodies

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Antiviral antibodies in the sera of homosexual men: correlation with their lifestyle and drug usage

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1310%2FHCT1302-90

21 January 2018

Identifiers

10.1310/HCT1302-90

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22510356

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51379841&oldid=1267470240"